Repatha (evolocumab) is a prescription drug used in certain situations to lower cholesterol and reduce serious heart-related risks. Repatha does this by attaching itself to a protein in your body ...

Dosage for Repatha (evolocumab) may vary based on the condition it’s being used to treat. You might take 140 milligrams (mg) or 420 mg every 2 weeks, or you might take 420 mg monthly.

The company’s Repatha (evolocumab) was added to optimised statin therapy in a phase 3 trial, and resulted in statistically significant regression of atherosclerosis in patients with coronary ...

More than four years after Amgen’s cholesterol-lowering antibody Repatha was approved in the US, the company still can’t generate much sales momentum behind the product. Its latest gambit is ...

Repatha and EVENITY are two medications that are producing significant growth for the company. On February 20, Bernstein analysts reduced the price target for Amgen (NASDAQ:AMGN) shares to $350 ...

It reported stronger profit for the latest quarter than expected, thanks in part to growth for its Repatha medicine, which can lower bad cholesterol and reduce the risk of heart attack.

Amgen’s diverse product portfolio continues to be a key strength, with several growth drivers emerging: Tezspire, Repatha, and Blincyto have shown solid performance, contributing to revenue growth.

To help new or inexperienced users get started with reliable benchmarking right away, we offer a quickstart guide that contains a brief explanation of the issues of common setups as well as the (few) ...

At close: 26 February at 4:50:01 pm GMT+1 ...